

Cunnup, Jillyan

From: Buse, John
Sent: Saturday, November 01, 2003 11:48 AM
To: 'CAVAZZONI PATRIZIA@Lilly.com'; Buse, John
Cc: 'ROYCHOWDHURY_SURAJA@Lilly.com'; 'CARLSON_CHRISTOPHER@Lilly.com'
Subject: RE: Letter needed for B J Psych

Was the letter that you sent correct? I made some modifications. Patrizia and Christopher, please feel free to make any further modifications that you feel is necessary. Patrizia, I give you authorization to have it printed out and faxed. I will be in a meeting at the NIH all day Monday. Tonya is authorized to forge such documents, but I have put an electronic signature on there as well. So when you are happy with the text, you could just print it. j

John Buse, MD, PhD, CDE
Associate Professor of Medicine
Chief, Div. of General Medicine and Clinical Epidemiology
Director, Diabetes Care Center
UNC School of Medicine
CB 7110; 5039 Old Clinic
Chapel Hill, NC 27599-7110

Academic office: 919-966-2276 ext 222 (Tonya Pope)
Fax: 919-966-2274
Clinic: 919-484-1015
Fax: 919-806-2181
Pager: 800-593-6916

-----Original Message-----

From: CAVAZZONI_PATRIZIA@Lilly.com [mailto:CAVAZZONI_PATRIZIA@Lilly.com]
Sent: Friday, October 31, 2003 2:38 PM
To: jbuse@med.unc.edu
Cc: ROYCHOWDHURY_SURAJA@Lilly.com; CARLSON_CHRISTOPHER@Lilly.com
Subject: Re: Letter needed for B J Psych

John

Could you please print letter (see attachment) , fill in appropriate spaces, sign and fax directly to Lilly UK as soon as possible on Monday AM

Attn: Chris Bushe

Fax number (44) 01256 775534.

We are hoping to send in all the paper by Monday lunch time (UK time)

Please let me know if this is not feasible, or if you need any assistance on our end

Thanks

Patrizia

CONFIDENTIAL SUBJECT TO PROTECTIVE ORDER: MDL 1596 (Zyprexa Litigation)

9/15/2004

62

BUSEHC000014

Chris
Bushe To: belucg@iol.ie, Patrizia Cavazzoni/AM/LLY@Lilly, "Prof. Ted Dinan" <tdinan@indigo.ie>, Kohen Dora
<Dora.Kohen@wiganlhs-tr.nwest.nhs.uk>, Dora.Kohen@wiganlhs-tr.nwest.nhs.uk, Richard Holt <R.I.G.Holt@soton.ac.uk>, Roychowdhury/AM/LLY@Lilly, Gough Stephen <Stephen.Gough@heartsol.wmids.nhs.uk>, Jogin Thakore <jthakore@indigo
31/10/2003 cc: Hiram Wildgust/EMA/LLY@Lilly
11:54 Subject: Letter needed for B J Psych

We need signed letters from each person relating to each manuscript that is being submitted to the journal. There is unfortunately a postal strike here in UK affecting many parts. maybe you could fill in the blanks in the template below or write your own letter/whichever is easiest and fax it back to me before midday on monday. The template also adds in that each of you are also of course co-authors of the consensus statement. Each named author of each paper has to submit such a letter in accordance with the rules of the journal.

Thanks for all your help here.

Chris

Dr Chris Bushe MB BS
Clinical Research Physician
Eli Lilly and Company Limited
Lilly House
Priestley Road
Basingstoke RG24 9NL
England
United Kingdom

Telephone 01256 775971
Mobile 07734402161
e-mail bushe_chris@lilly.com

CONFIDENTIAL SUBJECT TO PROTECTIVE ORDER: MDL 1596 (Zyprexa Litigation)

63

9/15/2004

BUSEHC000015

The Editor
The British Journal of Psychiatry
17 Belgrave Square
London SW1X 8PG

Manuscript submission: **Retrospective Analysis of Risk Factors in Patients with Treatment-Emergent Diabetes during Clinical Trials of Antipsychotic Medications**

Dear Sir

On behalf of Margaret Sowell, M.D., Ph. D.; Nitai Mukhopadhyay, Ph.D.; Patrizia Cavazzoni, M.D.; Christopher Carlson, Ph.D.; Alan Breier, M.D. and myself, I am pleased to submit our manuscript for your consideration for publication in a supplement to the *British Journal of Psychiatry*.


This paper has been prepared based on our presentation at an expert consensus meeting held in Dublin in October 2003. The meeting was chaired by Professor Ted Dinan from the University College, Cork in Ireland.

I agree also to be a co-author on the consensus statement.

Our reason for developing this manuscript is that, in the light of growing evidence linking the use of antipsychotic medications with the development of diabetes, we believe there is now a pressing need for practical recommendations for the screening and management of diabetes risk in people with schizophrenia. It is our belief that people with schizophrenia should now be considered to be a high-risk group for the development of diabetes, and that clinical psychiatrists should take the lead in establishing diabetes screening programmes for their schizophrenia patients.

We look forward to hearing your feedback on our paper in due course.

Yours truly



John Buse, MD, PhD, CDE
Associate Professor of Medicine
Chief, Div. of General Medicine and Clinical Epidemiology
Director, Diabetes Care Center
UNC School of Medicine

CONFIDENTIAL SUBJECT TO PROTECTIVE ORDER: MDL 1596 (Zyprexa Litigation)

64

BUSEHC000016